Safety of the HPV bivalent and quadrivalent vaccines during pregnancy

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 258-262

  Forinash, Alicia B ^a   Yancey, Abigail M ^a   Pitlick, Jamie M ^a   Myles, Thomas D ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human papillomavirus vaccine; Pregnancy

Indexed keywords

BIVALENT HUMAN PAPILLOMA VIRUS VACCINE; HEPATITIS A VACCINE; PLACEBO; QUADRIVALENT HUMAN PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANENCEPHALUS; ARTICLE; CLEFT PALATE; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ECTOPIC PREGNANCY; FETUS DEATH; FOOT MALFORMATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; KIDNEY ANOMALY; LIVE BIRTH; MEDLINE; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCHIZENCEPHALY; SIDE EFFECT; SPONTANEOUS ABORTION; VACCINATION; WART VIRUS; ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; FEMALE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY COMPLICATIONS, INFECTIOUS;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VACCINATION;

EID: 79951859685     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P396     Document Type: Article

References (23)

1. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999;26:S2-7. DOI 10.1097/00007435-199904001-00002
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2007;56:1-24.
3. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
4. American Cancer Society. Human papillomavirus (HPV), cancer, and HPV vaccines. http://www.cancer.org/docroot/CRI/content/CRI-2-6x-FAQ-HPV-Vaccines. asp (accessed 2010 Aug 21).
5. Product information. Cervarix (human papillomavirus bivalent 16/18). Research Triangle Park, NC: GlaxoSmithKline, December 2009.
6. Product information. Gardasil (human papillomavirus bivalent 6/11/16/18). Whitehouse Station, NJ: Merck, December 2009.
7. Wise LD, Wolf JJ, Kaplanski CV, Pauley CJ, Ledwith BJ. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 2008;83:561-72. DOI 10.1002/bdrb.20174
8. Instructions for use of the reference guide. In: Briggs GG, Freeman RK, Yaffe SJ, ed. Drugs in pregnancy and lactation. 8th ed. Philidelphia, PA: Lippincott Williams and Wilkins, 2008:xix-xxiv.
9. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. BMJ 2010;340:c712. DOI 10.1136/bmj.c712
10. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine. A combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179-88. DOI 10.1097/AOG.0b013e3181c2ca21
11. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170-8. DOI 10.1097/AOG.0b013e3181c2a122
12. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2008. National vital statistics reports; 58(16)1-18. Hyattsville, MD: National Center for Health Statistics. 2010. www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-16.pdf (accessed 4 August 2010).
13. Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod 1996;11:406-12. (Pubitemid 26089196)
14. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1998;319:189-94. DOI 10.1056/NEJM198807283190401
15. Savitz DA, Hertz-Picciotto I, Poole C, Oshan AF. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev 2002;24:91-101. DOI 10.1093/epirev%2Fmxf006 (Pubitemid 36553832)
16. Ventura SJ, Abma JC, Mosher WD, Henshaw SK. Estimated pregnancy rates for the United States, 1990-2005: an update. National vital statistics reports; v58 (4):1-15. Hyattsville, MD: National Center for Health Statistics. 2009. www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-04.pdf (accessed 5 Aug 2010).
17. MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. National vital statistics reports; 57(8):1-20. Hyattsville, MD: National Center for Health Statistics. 2009. www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57-08. pdf (accessed 5 Aug 2010).
18. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccinepreventable diseases. 11th Edition. Washington DC: Public Health foundation, 2009. Appendix B. Vaccine excipient and Media Summary, by vaccine B15-19.
19. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccinepreventable diseases. 11th Edition. Washington DC: Public Health Foundation, 2009. Appendix B. Vaccine excipient and Media Summary, by excipient B8-14.
20. Didierlaurent AM, Morel S, Lockman L, et al. ASO4, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immunue response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97. DOI 10.4049/jimmunol.0901474
21. Centers for Disease Control and Prevention. Advisory committee on immunization practices workgroup on the use of vaccines during pregnancy and breastfeeding. Guiding principles for development of ACIP recommendations for vaccination during pregnancy and breastfeeding. April 2008. http://www.cdc.gov/ vaccines/recs/acip/downloads/preg-principles05-01-08.pdf (accessed 2010 Aug 20).
22. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:301-14. DOI 10.1016/S0140-6736(09)61248-4
23. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27. DOI 10.1056/NEJMoa061741